HitGen Inc. (SSE: 688222.SH), founded in 2012, is headquartered in Chengdu, China, with subsidiaries in Cambridge, UK and Houston, USA. HitGen is committed to building a world-class innovative biopharmaceutical enterprise and contributing to the better life and health of mankind. Engaged in the discovery and optimization of small molecules and nucleic acid drugs, HitGen dedicates itself to cultivating an internationally leading drug discovery and optimization system centered on four key technology platforms, including DNA-encoded library technology (including DEL design, synthesis and screening, and application expansion), fragment-based drug discovery and structure-based drug design technologies (FBDD/SBDD), synthetic therapeutic oligonucleotide technology (STO), and targeted protein degradation technology (TPD). It provides new molecular entities (NMEs) at different stages of research and development for the pharmaceutical industry, through its diversified business models including research and development services, out-licensing of projects at different R&D stages, and new drug launches in the long term, with an aim to address unmet clinical needs with innovative therapeutic solutions. As a leader in the field of DEL technology, HitGen has been committed to the development, application and improvement of DEL technology since its establishment. By June 30, 2022, HitGen’s DELs contains more than 1.2 trillion novel, diverse, drug-like small molecules and macrocyclic compounds. These compounds are members of DELs synthesized from many thousands of distinct chemical scaffolds, designed with tractable chemistry, and have yielded proven results for the discovery of small molecule leads against precedented and unprecedented classes of biological targets. Through systematic DEL compound design, HitGen DELs has involved the use of more than 6000 different types of chemical scaffolds, which includes most of the core scaffolds of currently approved small-molecule drugs and many privileged scaffolds of small-molecules in clinical trials, and the approximately 40,000 different building blocks. HitGen has approximately 20 in-house drug discovery projects at different stages of research and development, among which 4 have obtained IND approvals and entered into clinical trials. HitGen is in collaboration with pharmaceutical, biotech and chemical companies, foundations and research institutes in the Americas, Asia, Europe, Africa, and Oceania. For more information, please call +86-28-85197385, +1-508-840-9646 or visit www.hitgen.com. For business development: bd@hitgen.com | HitGen Inc. (SSE: 688222.SH), is a drug discovery research company with headquarters in Chengdu, China, and subsidiaries in Cambridge, UK and Houston, USA. HitGen has established leading technology platforms to enable the discovery and optimization of small molecules and nucleic acid drugs. Our key technology platforms include world-leading DNA-encoded library technology (DEL), fragment-based drug discovery and structure-based drug design technologies (FBDD/SBDD), as well as the emerging technology platforms for synthetic therapeutic oligonucleotide technology (STO), and targeted protein degradation technology (TPD). Through our diverse and flexible business models, we have built up collaboration partnership with several hundred biopharmaceutical research organizations worldwide. HitGen has multiple programmes from early discovery to clinical trial stage. | About HitGen Inc. HitGen Inc. (SSE: 688222.SH), is a drug discovery research company headquartered in Chengdu, China, with subsidiaries in Cambridge, UK and Houston, USA. HitGen has established leading technology platforms to enable the discovery and optimization of small molecules and nucleic acid-based drugs. Our key technology platforms include world-leading DNA-encoded library technology (DEL), fragment-based drug discovery and structure-based drug design technologies (FBDD/SBDD), as well as the emerging technology platforms for oligonucleotide-based therapeutics (OBT), and targeted protein degradation technology (TPD). Meanwhile, we are developing a DEL+AI+ Automated DMTA (Design-Make-Test-Analyze) molecular optimization platform to accelerate the discovery and optimization process of preclinical candidate compounds. Through our diverse and flexible business models, we have built up collaboration partnerships with several hundred biopharmaceutical research organizations worldwide. HitGen has multiple programmes from early discovery to clinical trial stage.
HIPRA Biotech Services
HIPRA Biotech Services is a CDMO supporting pharmaceutical and biotech companies across the full early clinical to commercial lifecycle of biologic and vaccine products. Backed by over 50 years of scientific and technical excellence including our internally commercialized and marketed COVID vaccine, we offer end-to-end development and GMP manufacturing solutions across a wide range of expression platforms, from viral to mammalian to microbial platforms, to make clinical and commercial drug substance and drug product for our clients. With a team of 450+ R&D scientists and over 1,000+ professionals in Manufacturing, QA and QC, state-of-the-art facilities, and a strong regulatory track record, we deliver both clinical and commercial programs with speed, quality, and flexibility. We continuously invest in innovation and capacity expansion, making us a trusted partner that will grow with our clients for their long-term success. https://www.hipra.com/en/cdmo-services
HANS Scientific
HANS Scientific is your nimble partner for CMO and WFI Generation. Our on-staff engineering and regulatory teams enable us to ramp projects quickly and with flexibility to meet your requirements. We are an agile, US-Based CMO with aseptic Fill/Finish and ALUS Lyophilization chamber. Highly innovative WFI generation equipment designed/built in the US, and bulk WFI in Bioprocess containers are readily available.
H&T Presspart
H&T Presspart is a world leader and specialist in manufacturing drug delivery devices and pharmaceutical components. With 50 years experience in partnering with the world’s leading pharma companies we have developed a strong reputation for precision and reliability – critically important when patients’ quality of life depends on our products. Our extensive skills and experience cover drug delivery device development and industrialisation and every aspect of high-volume precision deep-drawn manufacturing, injection moulding and high-speed assembly in ISO 7 and ISO 8 cleanrooms.
Groupe PARIMA
Groupe PARIMA is a Contract Development and Manufacturing Organization (CDMO), established in 1994. Over the years, we have developed an expertise in the development and manufacturing of non-sterile liquids, suspensions, and semi-solid drug products. This strategic focus has allowed us to establish a unique expertise to support your product development and manufacturing needs, which, combined to our operational flexibility and commitment to delivering on time, enables us to operate as an extension of your team. Our business is 100% fee-for-service and exclusively focused on contract services. We are here to help you meet your company objectives, not to compete with you. | Groupe PARIMA is a leading Contract Development & Manufacturing Organization (CDMO) that excels in the development and manufacturing of non-sterile pharmaceutical products. Specializing in liquids, semi-solids, and suspensions, we offer an extensive range of services focused on product development, commercial manufacturing, packaging and laboratory testing. Our modern facility is equipped to handle complex pharmaceutical formulations and packaging requirements. At the core of our operation is a deep commitment to research and development. Our expert team collaborates closely with clients to design and optimize formulations that meet specific patient needs, ensuring each product achieves optimal effectiveness and regulatory approval. This focus on development is complemented by our flexibility to scale processes seamlessly from pilot batches to clinical supply and eventually large-scale commercial production. Our team of skilled professionals bring a wealth of industry knowledge and technical expertise, making us a preferred partner for both emerging biotechs and established pharmaceutical companies across 28 countries. Groupe PARIMA’s ability to adapt swiftly to changing market conditions and client requirements sets us apart in the dynamic pharmaceutical landscape. With ample manufacturing capacity and comprehensive on-site services including laboratory testing and regulatory compliance activities, we are equipped to handle diverse project demands with precision. Whether advancing a novel treatment or expanding production capabilities, Groupe PARIMA provides the expertise and infrastructure necessary to bring your pharmaceutical products to global markets. Explore the possibilities with Groupe PARIMA as your dedicated CDMO partner. Discover our full range of development capabilities and services at www.groupeparima.com. | Groupe PARIMA, a CDMO since 1994, specializes in the development and manufacturing of non-sterile liquids, suspensions, and semi-solids. With deep expertise in complex formulations, scale-up, and regulatory compliance, we provide end-to-end support from development to commercial production. Our flexible approach, technical proficiency, and commitment to on-time delivery make us a trusted partner for pharmaceutical companies worldwide. As a dedicated contract service provider, we focus entirely on supporting our clients’ success with tailored solutions and operational agility.
GfM Milling and Micronization Services LLC.
GfM, founded in 1985 in Bremen, Germany, is the world’s largest independent, family-owned micronization CMO. We refine APIs, excipients, and other products to the highest cGMP standards for the pharmaceutical, chemical, food, nutraceutical, and cosmetic industries. Expanding to the U.S., we’ll support projects from our new Bethlehem, PA facility in 2026, bringing expertise in particle size reduction and analysis to meet your production needs.
Forge Biologics
Forge Biologics is a hybrid gene therapy contract manufacturing and clinical-stage therapeutics development company. Forge’s mission is to enable access to life changing gene therapies and help bring them from idea to reality. Forge’s 200,000 square foot facility utilizes 20 cGMP suites in Columbus, Ohio, the Hearth, to serve as its headquarters. The Hearth is a custom-designed cGMP facility dedicated to AAV manufacturing and hosts scalable, end-to-end manufacturing services. Offerings include process and analytical development, plasmid DNA manufacturing, viral vector manufacturing, final fill, as well as regulatory consulting support to accelerate gene therapy programs from preclinical through clinical and commercial stage manufacturing. By taking a patients-first approach, Forge aims to accelerate the timelines of these transformative medicines for those who need them the most. To learn more, visit www.forgebiologics.com. | Forge Biologics, a member of Ajinomoto Biopharma Services, is a hybrid gene therapy contract manufacturing and clinical-stage therapeutics development company, enabling access to life-changing gene therapies by bringing them from concept to reality. Forge’s 200,000 square foot facility, the Hearth, is headquartered in Columbus, Ohio, and houses 20 custom-designed cGMP suites. Forge’s end-to-end, scalable plasmid and AAV manufacturing services include research-grade manufacturing, process and analytical development, cGMP manufacturing, fill and finish, and regulatory consulting support to help accelerate the timelines of transformative medicines for patients with genetic diseases. To learn more, visit www.forgebiologics.com. | Forge Biologics, a member of Ajinomoto Bio-Pharma Services, is a gene therapy contract development and manufacturing organization (CDMO) enabling access to life-changing gene therapies by bringing them from concept to reality. Forge’s 200,000 square foot facility, the Hearth, is headquartered in Columbus, Ohio, and houses 20 custom-designed cGMP suites with 20,000L of bioreactor capacity. Forge’s end-to-end, scalable plasmid and AAV manufacturing services include research-grade manufacturing, process and analytical development, cGMP manufacturing, fill and finish, and integrated regulatory support to help accelerate the timelines of transformative medicines for patients with genetic diseases. To learn more, visit www.forgebiologics.com | Forge Biologics, a member of Ajinomoto Bio-Pharma Services, is a gene therapy contract development and manufacturing organization (CDMO) enabling access to life-changing gene therapies by bringing them from concept to reality. Forge’s 200,000 square foot facility, the Hearth, is headquartered in Columbus, Ohio, and houses 20 custom-designed cGMP suites with 20,000L of bioreactor capacity. Forge’s end-to-end, scalable plasmid and AAV manufacturing services include research-grade manufacturing, process and analytical development, cGMP manufacturing, fill and finish, and integrated regulatory support to help accelerate the timelines of transformative medicines for patients with genetic diseases.
Fluid Air
Established in 1983, Fluid Air serves companies that manufacture powdered products and ingredients, in industries including biopharmaceutical, advanced batteries, nutraceutical, food, fine chemicals, and agriculture. Our PolarDry® electrostatic drying system allows customers to bypass the inherent constraints of freeze drying and conventional spray drying, achieving scalable production and lower costs. Learn more about Fluid Air at www.fluidairinc.com.
FAREVA
Farera as a CDMO is providing a large service offer as sterile injectable and high potent, biological drug, conventionnal product, medial devices, foods supllements and probiotics as well as Drug substance manufacturing of recombinant protein, Andibody Dug Conjugason (ADC) with the associated Fill& Finish | FAREVA is a leading global pharmaceutical CDMO with industry leading capabilities in the development and manufacturing of a large range of Drug Products and Active Pharmaceutical Ingredients (APIs). FAREVA employs 13,000 people distributed in 41 production sites located in 13 countries in EMEA and the Americas. 16 of the FAREVA sites are dedicated to pharmaceutical activities. FAREVA’s API division has operations in 3 European sites located in France and Germany. | Fareva is a leading global pharmaceutical CDMO with a network of 16 manufacturing sites and 3 development sites throughout EMEA and the Americans. We offer comprehensive drug product and API services, including formulation development, clinical manufacturing, scale-up, and commercial manufacturing of small and large molecules. Our capabilities cover a wide range of dosage forms, such as OTC products, oral solid doses, non-sterile liquids and solids, ophthalmics, as well as sterile fill/finish and lyophilized presentations. In addition, our facilities have extensive expertise in secondary packaging, enabling us to serve as a fully integrated partner for our clients’ end-to-end pharmaceutical needs.
Experic
Experic is a contract development and manufacturing organization (CDMO) and clinical trial supply services company dedicated to revolutionizing pharmaceutical development, manufacturing, and clinical trial supply. Established in 2018, Experic offers a comprehensive suite of services, including process development, analytical and formulation development, clinical and commercial manufacturing, and clinical packaging and logistics. Specializing in challenging powders and inhalation products, our expertise encompasses tablets, pellets, capsules, and low-dose dry powder inhalation therapies. Operating from our state-of-the-art, Class A cGMP facility in Cranbury, New Jersey, we manage the global delivery of high-quality products, even for expedited projects. Our team of industry leaders brings decades of experience in pharmaceutical product development and clinical trial supplies, ensuring strategic vision and execution for every project. At Experic, we are committed to delivering innovative, client-focused services that accelerate the development and commercialization of life-changing therapies. Our flexible, customer-oriented approach addresses the growing needs of the biopharmaceutical industry, making us a trusted partner in bringing innovative products to market.